Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Argan (AGX) Cash & Equivalents: 2009-2025

Historic Revenue - Interest and Investment Income for Argan (AGX) over the last 2 years, with Jan 2014 value amounting to $156.3 million.

  • Argan's Cash & Equivalents rose 74.68% to $306.3 million in Q4 2025 from the same period last year, while for Oct 2025 it was $306.3 million, marking a year-over-year increase of 74.68%. This contributed to the annual value of $145.3 million for FY2025, which is 26.27% down from last year.
  • Latest data reveals that Argan reported Cash & Equivalents of $306.3 million as of Q4 2025, which was up 72.22% from $177.8 million recorded in Q3 2025.
  • Argan's 5-year Cash & Equivalents high stood at $451.4 million for Q3 2021, and its period low was $136.1 million during Q4 2022.
  • Moreover, its 3-year median value for Cash & Equivalents was $192.6 million (2023), whereas its average is $199.3 million.
  • As far as peak fluctuations go, Argan's Revenue - Interest and Investment Income dropped by 9.63% in 2011, and later rose by 29.27% in 2014.
  • Argan's Revenue - Interest and Investment Income (Quarterly) stood at $134.3 million in 2010, then dropped by 9.63% to $111.5 million in 2011, then reached $120.9 million in 2013, then grew by 29.27% to $156.3 million in 2014.
  • Its Cash & Equivalents stands at $306.3 million for Q4 2025, versus $177.8 million for Q3 2025 and $189.3 million for Q2 2025.